Radioligand therapy is widely recognized as one of the most promising next-generation cancer treatment modalities. Yet, the field continues to face two critical challenges: identifying which patients will benefit the most, and establishing reliable, standardized ways to assess treatment response. Studies show that as many as 54% of those undergoing therapy may not benefit at all, underscoring the need for early identification to prevent ineffective therapy and pivot to more effective alternatives. At the same time, for patients who do respond, physicians can use precise, quantitative insights to tailor treatment to maximize long-term benefit and minimize unnecessary exposure. TrackPSMA uses AI to automatically analyze PSMA-PET/CT scans from the same patient over time, helping physicians monitor patient treatment response, identify disease progression early and make more timely decisions to optimize care–whether by adjusting dosage, or switching to a more effective treatment option.

TrackPSMA delivers a comparative assessment, quantifying disease changes from screening and follow-up scans, vastly improving a process that is often unstructured, manual, visually evaluated and inconsistently applied. In addition, TrackPSMA enables lesion-by-lesion tracking for true longitudinal analysis, allowing clinicians to monitor changes in individual lesions over time. The result is a standardized and evidence-based assessment, available in seconds, that gives physicians the confidence and rigor to act sooner for data-driven decisions.